KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Astrazeneca (AZN) Receivables Refunds (2016 - 2025)

Astrazeneca has reported Receivables Refunds over the past 11 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Receivables Refunds at $1.2 billion for Q4 2025, down 37.71% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (down 37.71% YoY), and the annual figure for FY2025 was $1.2 billion, down 37.71%.
  • Receivables Refunds for Q4 2025 was $1.2 billion at Astrazeneca, down from $1.9 billion in the prior quarter.
  • Over the last five years, Receivables Refunds for AZN hit a ceiling of $1.9 billion in Q4 2024 and a floor of $663.0 million in Q4 2021.
  • Median Receivables Refunds over the past 5 years was $1.2 billion (2025), compared with a mean of $1.2 billion.
  • Biggest five-year swings in Receivables Refunds: soared 95.08% in 2023 and later crashed 37.71% in 2025.
  • Astrazeneca's Receivables Refunds stood at $663.0 million in 2021, then rose by 10.26% to $731.0 million in 2022, then soared by 95.08% to $1.4 billion in 2023, then surged by 30.36% to $1.9 billion in 2024, then tumbled by 37.71% to $1.2 billion in 2025.
  • The last three reported values for Receivables Refunds were $1.2 billion (Q4 2025), $1.9 billion (Q4 2024), and $1.4 billion (Q4 2023) per Business Quant data.